The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Open accessAbstract
BACKGROUND: The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly. We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study. METHODS: A total of 1493 patients with schizophrenia were recruited at 57 U.S. sites and randomly assigned to receive olanzapine (7.5 to 30 mg per day), perphenazine (8 to 32 mg per day), quetiapine (200 to 800 mg per day), or risperidone (1.5 to 6.0 mg per day) for up to 18 months. Ziprasidone (40 to 160 mg per day) was included after its approval by the Food and Drug Administration. The primary aim was to delineate differences in the overall effectiveness of these five treatments. RESULTS: Overall, 74 percent of patients discontinued the study medication before 18 months (1061 of the 1432 patients who received at least one dose): 64 percent of those assigned to olanzapine, 75 percent of those assigned to perphenazine, 82 percent of those assigned to quetiapine, 74 percent of those assigned to risperidone, and 79 percent of those assigned to ziprasidone. The time to the discontinuation of treatment for any cause was significantly longer in the olanzapine group than in the quetiapine (P<0.001) or risperidone (P=0.002) group, but not in the perphenazine (P=0.021) or ziprasidone (P=0.028) group. The times to discontinuation because of intolerable side effects were similar among the groups, but the rates differed (P=0.04); olanzapine was associated with more discontinuation for weight gain or metabolic effects, and perphenazine was associated with more discontinuation for extrapyramidal effects. CONCLUSIONS: The majority of patients in each group discontinued their assigned treatment owing to inefficacy or intolerable side effects or for other reasons. Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone. Olanzapine was associated with greater weight gain and increases in measures of glucose and lipid metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An example of an early precursor to the SMART is the Clinical Antipsychotics Trial of Intervention Effectiveness (CATIE) [54] in chronic schizophrenia.”
From Introduction to SMART designs for the development of adaptive interventions: with application to weight loss research (2014) · cites this paper as [54]
In the citing paper
“In schizophrenia, for example, recent studies have shown that since the introduction of second-generation antipsychotics, treatment efficacy has only marginally improved over traditional dopamine D-2 antagonists, which were introduced 50 years ago (Lieberman et al., 2005”
From Neuronal Dynamics and Neuropsychiatric Disorders: Toward a Translational Paradigm for Dysfunctional Large-Scale Networks (2012) · cites this paper as Lieberman et al., 2005
In the citing paper
“While effective in reducing the positive symptoms, the cognitive dysfunctions and negative symptoms, two major determinants for outcome and level of functioning, remained unchanged in the large majority of patients.”
From Neuronal Dynamics and Neuropsychiatric Disorders: Toward a Translational Paradigm for Dysfunctional Large-Scale Networks (2012) · cites this paper as Lieberman et al., 2005
In the citing paper
“Over the last 50 years, the pharmacological therapy of schizophrenia was based mainly on the dopamine hypothesis and made little progress (Lieberman et al., 2005”
From Neuronal Dynamics and Neuropsychiatric Disorders: Toward a Translational Paradigm for Dysfunctional Large-Scale Networks (2012) · cites this paper as Lieberman et al., 2005
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Tunis (2003) · doi:10.1001/jama.290.12.1624 · Cited by 1,724
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Geddes, J. R., Freemantle, N., Harrison, P. J., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,056
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,022
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Self-citationLeucht, S., Pitschel‐Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 795
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,049
Cunill, R., Castells, X., Tobias, A., & Capellà, D. (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3473 · Cited by 70
Substance use and schizophrenia: adverse correlates in the CATIE study sample
Kerfoot, K. E., Rosenheck, R. A., Petrakis, I. L., Swartz, M. S., Keefe, R. S. E., McEvoy, J. P., & Stroup, T. S. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.07.032 · Cited by 70
Self-citationBenson, K. L. (2015) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2014.11.001 · Cited by 70
Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling.
Noetzel, M. J., Jones, C. K., & Conn, P. J. (2012) · PubMed · Cited by 70
Timbie, J. W., Fox, D. S., Busum, K. R. V., & Schneider, E. C. (2012) · Health Affairs · doi:10.1377/hlthaff.2012.0150 · Cited by 70
Biological Aspects of Aggression and Violence in Schizophrenia
Cho, W., Shin, W., An, I., Bang, M., Cho, D., & Lee, S.-H. (2019) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2019.17.4.475 · Cited by 70
Soria‐Chacartegui, P., Villapalos‐García, G., Zubiaur, P., Abad‐Santos, F., & Koller, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.711940 · Cited by 70
Brook, O. H., van Hout, H. P. J., Stalman, W. A. B., & de Haan, M. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000246217.34024.53 · Cited by 70
Srisurapanont, M., Suttajit, S., Maneeton, N., & Maneeton, B. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.01.004 · Cited by 70
Alkelai, A., Greenbaum, L., Rigbi, A., Kanyas, K., & Lerer, B. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1627-z · Cited by 70
Glycogen synthase kinase 3 substrates in mood disorders and schizophrenia
Cole, A. R. (2013) · FEBS Journal · doi:10.1111/febs.12407 · Cited by 70
Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia
Tardy, M., Huhn, M., Kissling, W., Engel, R. R., & Leucht, S. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009268.pub2 · Cited by 70
Gustafsson, M. V., Karlsson, S., & Lövheim, H. (2013) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-14-10 · Cited by 70
Möller, H., Riedel, M. J., Jäger, M., Wickelmaier, F., Maier, W., Kühn, K.-U., Buchkremer, G., Heuser, I., Klosterkötter, J., Gastpar, M., et al. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708008791 · Cited by 70
A preclinical and clinical rationale for quetiapine in mood syndromes
McIntyre, R. S., Soczynska, J. K., Woldeyohannes, H. O., Alsuwaidan, M. T., & Konarski, J. Z. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.9.1211 · Cited by 70
Time Course of the Antipsychotic Effect and the Underlying Behavioral Mechanisms
Li, M., Fletcher, P. J., & Kapur, S. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301110 · Cited by 70
Treatment of Bipolar Disorder in a Lifetime Perspective: Is Lithium Still the Best Choice?
Sani, G., Perugi, G., & Tondo, L. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0531-2 · Cited by 70
Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants
Saiz‐Rodríguez, M., Belmonte, C., Román, M. C., Ochoa, D., Jiang‐Zheng, C., Koller, D., Mejía-Abril, G. P., Zubiaur, P., Wojnicz, A., & Abad‐Santos, F. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13031 · Cited by 70
Quetiapine versus other atypical antipsychotics for schizophrenia
Asmal, L., Flegar, S. J., Wang, J., Rummel‐Kluge, C., Komossa, K., & Leucht, S. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006625.pub3 · Cited by 70
Trends in Psychiatry and Psychotherapy
(2020) · Trends in Psychiatry and Psychotherapy · doi:10.47626/2237-6089 · Cited by 70
Implications of the CATIE Trial on Treatment: Extrapyramidal Symptoms
Casey, D. E. (2006) · CNS Spectrums · doi:10.1017/s1092852900026651 · Cited by 69
Zhang, J., Robinson, D. G., Gallego, J. A., John, M., Yu, J., Addington, J., Tohen, M. F., Kane, J. M., Malhotra, A. K., & Lencz, T. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv116 · Cited by 69
Kumra, S., Kranzler, H. N., Gerbino-Rosen, G., Kester, H. M., DeThomas, C., Cullen, K., Regan, J., & Kane, J. M. (2008) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0089 · Cited by 69
Cooper, G. D., Harrold, J. A., Halford, J. C. G., & Goudie, A. J. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.09.012 · Cited by 69
Hwang, R., Zai, C. C. H., Tiwari, A. K., Müller, D., Arranz, M. J., Morris, A. G., McKenna, P. J., Munro, J., Potkin, S. G., Lieberman, J. A., et al. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.65 · Cited by 69
Self-citationSystematic analysis of dopamine receptor genes (DRD1–DRD5) in antipsychotic-induced weight gain
Müller, D., Zai, C. C. H., Sicard, M. N., Remington, E., de Souza, R. P., Tiwari, A. K., Hwang, R., Likhodi, O., Shaikh, S. A., Freeman, N., et al. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.65 · Cited by 69
Self-citationCastro‐Fornieles, J., Parellada, M., Soutullo, C. A., Baeza, I., González-Pinto, A. M., Graell, M., Payá, B., Moreno, D. M., de la Serna, E., & Arango, C. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0138 · Cited by 69
Gunes, A., Scordo, M. G., Jaanson, P., & Dahl, M. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0622-x · Cited by 69
Treatment Outcomes of Patients With Tardive Dyskinesia and Chronic Schizophrenia
Caroff, S. N., Davis, V. G., Miller, D. D., Thomas, S., Rosenheck, R. A., McEvoy, J. P., Campbell, E. C., Saltz, B. L., Riggio, S., Chakos, M., et al. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05793yel · Cited by 69
Self-citationOfford, S. J., Lin, J., Mirski, D. F., & Wong, B. J. O. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0016-5 · Cited by 69
Off-Label Use of Second-Generation Antipsychotic Agents Among Elderly Nursing Home Residents
Kamble, P., Sherer, J. T., Chen, H., & Aparasu, R. R. (2010) · Psychiatric Services · doi:10.1176/ps.2010.61.2.130 · Cited by 69
Clinical Social Work and the Biomedical Industrial Complex
Gomory, T., Wong, S. E., Cohen, D., & Lacasse, J. R. (2011) · The Journal of Sociology & Social Welfare · doi:10.15453/0191-5096.3635 · Cited by 69
Cariprazine in the treatment of schizophrenia
Durgam, S., Litman, R. E., Papadakis, K., Li, D., Németh, G., & Laszlovszky, I. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000110 · Cited by 69
de León, J., Greenlee, B., Barber, J. W., Sabaawi, M., & Singh, N. N. (2008) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2008.10.010 · Cited by 69
End Points in Advanced Colon Cancer Clinical Trials: A Review and Proposal
Allegra, C. J., Blanke, C. D., Buyse, M. E., Goldberg, R. M., Grothey, A. F., Meropol, N. J., Saltz, L. B., Venook, A. P., Yothers, G., & Sargent, D. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1368 · Cited by 69
BURTON, S. C. (2005) · Journal of Psychiatric Practice · doi:10.1097/00131746-200511000-00003 · Cited by 68
Park, T., Usher, K. J., & Foster, K. (2011) · International Journal of Mental Health Nursing · doi:10.1111/j.1447-0349.2011.00747.x · Cited by 68
Atypical antipsychotics: new drugs, new challenges.
Mathews, M., & Muzina, D. J. (2007) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.74.8.597 · Cited by 68
Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches
Kantrowitz, J. T. (2020) · CNS Drugs · doi:10.1007/s40263-020-00752-2 · Cited by 68
Uliana, D. L., Lisboa, J. R., Gomes, F. V., & Grace, A. A. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116298 · Cited by 71
Suratman, S., Leach, K., Sexton, P. M., Felder, C. C., Loiacono, R. E., & Christopoulos, A. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01184.x · Cited by 68
Management of Schizophrenia with Obesity, Metabolic, and Endocrinological Disorders
Monteleone, P., Martiadis, V., & Maj, M. (2009) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.08.003 · Cited by 70
Daumit, G. L., Dalcin, A., Jerome, G. J., Young, D. R., Charleston, J. B., Crum, R. M., Anthony, C. B., Hayes, J., McCarron, P. B., Khaykin, E., et al. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.224 · Cited by 68
Risk profiles for non‐adherence to antipsychotic medications
McCann, T. V., BOARDMAN, G., Clark, E., & Lu, L. (2008) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/j.1365-2850.2008.01277.x · Cited by 68
Genetic variation in CYP3A43 explains racial difference in olanzapine clearance
Bigos, K. L., Bies, R. R., Pollock, B. G., Lowy, J. J., Zhang, F., & Weinberger, D. R. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.38 · Cited by 68
Risperidone long-acting injection: a review of its long term safety and efficacy
Rainer, M. K. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s3311 · Cited by 68
Zhang, J., Lencz, T., Geisler, S., DeRosse, P., Bromet, E. J., & Malhotra, A. K. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.01.020 · Cited by 68
Emerging drugs for schizophrenia
Agid, O., Kapur, S., & Remington, G. J. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.3.479 · Cited by 68
Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism
Oh, K., Park, J., Lee, S. Y., Hwang, I., Kim, J. B., Park, T., Lee, H., & Koo, S. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00502.2010 · Cited by 68
Ghotbi, R., Mannheimer, B., Aklillu, E., Suda, A., Bertilsson, L., Eliasson, E., & Ösby, U. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0783-8 · Cited by 68
Lian, J., Huang, X., Pai, N. B., & Deng, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104160 · Cited by 68
Moritz, S., Veckenstedt, R., Randjbar, S., Hottenrott, B., Woodward, T. S., von Eckstaedt, F. V., Schmidt, C. S., Jelinek, L., & Lincoln, T. M. (2009) · Psychological Medicine · doi:10.1017/s0033291709005923 · Cited by 68
Advances in psychotropic formulations
Keith, S. J. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.03.031 · Cited by 68
Mamo, D. C., Kapur, S., Keshavan, M. S., Laruelle, M. A., Taylor, C. C., Kothare, P. A., Barsoum, P., & McDonnell, D. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301409 · Cited by 68
Nordquist, R. E., Risterucci, C., Moreau, J., von Kienlin, M., Künnecke, B., Maco, M., Freichel, C., Riemer, C., & Spooren, W. P. J. M. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.10.010 · Cited by 68
The Choice of Antipsychotic Drugs for Schizophrenia
Freedman, R. (2005) · New England Journal of Medicine · doi:10.1056/nejme058200 · Cited by 68
Medicinal chemistry strategies in follow-on drug discovery
Zhao, H., & Guo, Z. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.02.008 · Cited by 68
Ventura, J., Reise, S. P., Keefe, R. S. E., Hurford, I. M., Wood, R. C., & Bilder, R. M. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs001 · Cited by 67
Self-citationTor, P. C., Tan, X. W., Martin, D. M., & Loo, C. K. A. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.04.023 · Cited by 67
Reliability of an fMRI paradigm for emotional processing in a multisite longitudinal study
Gee, D. G., McEwen, S. C., Forsyth, J. K., Haut, K. M., Bearden, C. E., Addington, J., Goodyear, B. G., Cadenhead, K. S., Mirzakhanian, H., Cornblatt, B. A., et al. (2015) · Human Brain Mapping · doi:10.1002/hbm.22791 · Cited by 67
Self-citationCai, J., Zhang, W., Yi, Z., Lu, W., Wu, Z., Chen, J., Yu, S., Fang, Y., & Zhang, C. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3137-2 · Cited by 67
de Sá, A. R., Hounie, A. G., Sampaio, A. S., Arrais, J., Miguel, E. C., & Elkis, H. (2009) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2008.11.005 · Cited by 67
Sexual functioning, psychopathology and quality of life in patients with schizophrenia
Fan, X., Henderson, D. C., Chiang, E., Briggs, L. B. N., Freudenreich, O., Evins, A. E., Cather, C., & GOFF, D. C. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.04.033 · Cited by 67
A Randomized Clinical Trial of Histamine 2 Receptor Antagonism in Treatment-Resistant Schizophrenia
Meskanen, K., Ekelund, H., Laitinen, J., Neuvonen, P. J., Haukka, J. K., Panula, P., & Ekelund, J. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182970490 · Cited by 67
Casey, D. E., Sands, E. E., Heisterberg, J., & Yang, H.-M. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1207-7 · Cited by 67
Reisberg, ., Monteiro, I. M., Torossian, C. L., Auer, S., Shulman, M. B., Ghimire, S., Boksay, I., Guillo‐Benarous, F., Osorio, R. S., Vengassery, A., et al. (2014) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000357839 · Cited by 67
New generation antipsychotic drugs and compliance behaviour
Voruganti, L. P., Baker, L. K., & Awad, A. G. (2008) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3282f52851 · Cited by 67
Bishara, D., Olofinjana, O., Sparshatt, A., Kapur, S., Taylor, D. M., & Patel, M. X. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31828b28d5 · Cited by 67
Clozapine use in children and adolescents
Gogtay, N., & Rapoport, J. L. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.3.459 · Cited by 67
Fleeman, N., McLeod, C., Bagust, A., Beale, S., Boland, A., Dundar, Y., Jorgensen, A., Payne, K., Pirmohamed, M., Pushpakom, S. P., et al. (2010) · Health Technology Assessment · doi:10.3310/hta14030 · Cited by 67
Risperidone Maintenance Treatment in Schizophrenia: A Randomized, Controlled Trial
Wang, C., Xiang, Y., Cai, Z., Weng, Y., Bo, Q., Zhao, J., Liu, T., Wang, G., Weng, S.-M., Zhang, H., et al. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030358 · Cited by 67
Pharmacogenetics of antipsychotic-induced side effects
Lencz, T., & Malhotra, A. K. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.4/tlencz · Cited by 67
Antipsychotics inhibit TREK but not TRAAK channels
Thümmler, S., Duprat, F., & Lazdunski, M. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.12.199 · Cited by 67
Atypical antipsychotics for psychosis in adolescents
Kumar, A., Datta, S. S., Wright, S., Furtado, V. A., & Russell, P. S. S. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009582.pub2 · Cited by 66
Cuerda, C., Velasco, C., Merchán‐Naranjo, J., García-Peris, P., & Arango, C. (2013) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2013.253 · Cited by 66
Gäebel, W., Riesbeck, M., von Wilmsdorff, M., Burns, T., Derks, E. M., Kahn, R. S., Wulf Rössler, A., & Fleischhacker, W. W. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.02.001 · Cited by 66
Insight and subjective measures of quality of life in chronic schizophrenia
SIU, C. O., Harvey, P. D., Agid, O., Waye, M. M. Y., Brambilla, C., Choi, W.-K., & Remington, G. J. (2015) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2015.05.002 · Cited by 66
Sacchetti, E., Galluzzo, A., Valsecchi, P., Romeo, F., Gorini, B., & Warrington, L. E. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.02.017 · Cited by 66
Aggression in Persons with Dementia: Use of Nursing Theory to Guide Clinical Practice
Dettmore, D., Kolanowski, A. M., & Boustani, M. A. (2009) · Geriatric Nursing · doi:10.1016/j.gerinurse.2008.03.001 · Cited by 66
Clinical Features of Schizophrenia With Enhanced Carbonyl Stress
Miyashita, M., Arai, M., Kobori, A., Ichikawa, T., Toriumi, K., Niizato, K., Oshima, K., Okazaki, Y., Yoshikawa, T., Amano, N., et al. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt129 · Cited by 66
Gardell, L. R., Vanover, K. E., Pounds, L., Johnson, R. W., Barido, R., Anderson, G. T., Veinbergs, I., Dyssegaard, A., Brunmark, P., Tabatabaei, A., et al. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.121715 · Cited by 66
Perez, S. M., Carreno, F. R., Frazer, A., & Lodge, D. J. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0588-14.2014 · Cited by 65
Effect of Antipsychotic Medications on Glucose and Lipid Levels
Chaggar, P. S., Shaw, S. M., & Williams, S. G. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010368678 · Cited by 65
Morrison, P., Meehan, T., & Stomski, N. J. (2014) · International Journal of Mental Health Nursing · doi:10.1111/inm.12110 · Cited by 65
Gunes, A., Dahl, M., Spina, E., & Scordo, M. G. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0450-x · Cited by 65
Another view of the history of antipsychotic drug discovery and development
Carpenter, W. T., & Davis, J. M. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.121 · Cited by 65
Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients
Ruaño, G., Goethe, J. W., Caley, C. F., Woolley, S. B., Holford, T. R., Kocherla, M., Windemuth, A., & de León, J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001944 · Cited by 65
Zhu, B., Ascher‐Svanum, H., Shi, L., Faries, D. E., Montgomery, W. S., & Marder, S. R. (2008) · Psychiatric Services · doi:10.1176/ps.2008.59.3.315 · Cited by 65
Mitchell, A., Jiang, Y., Peter, C. J., & Akbarian, S. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.10.020 · Cited by 65
Hiemke, C. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0430-1 · Cited by 65
The Presynaptic Component of the Serotonergic System is Required for Clozapine's Efficacy
Yadav, P. N., Abbas, A. I., Farrell, M. S., Setola, V., Sciaky, N., Huang, X., Kroeze, W. K., Crawford, L. K., Piel, D., Keiser, M. J., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.195 · Cited by 65
Rabinowitz, J., Levine, S. Z., Barkai, O., & Davidov, O. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn005 · Cited by 65
Naughton, M., Nulty, A., Abidin, Z., Davoren, M., O’Dwyer, S., & Kennedy, H. G. (2012) · BMC Research Notes · doi:10.1186/1756-0500-5-302 · Cited by 65
Recent advances in understanding schizophrenia
Haller, C. S., Padmanabhan, J. L., Lizano, P. L., Torous, J. B., & Keshavan, M. S. (2014) · F1000Prime Reports · doi:10.12703/p6-57 · Cited by 65
Barnes, T. R. E., Leeson, V. C., Paton, C., Costelloe, C., Simon, J., Kiss, N., Osborn, D., Killaspy, H. T., Craig, T., Lewis, S. W., et al. (2016) · Health Technology Assessment · doi:10.3310/hta20290 · Cited by 65
Psychosis in Children and Adolescents
McClellan, J. (2018) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2018.01.021 · Cited by 65
Toward personalized medicine in schizophrenia: Genetics and epigenetics of antipsychotic treatment
Lisoway, A. J., Chen, C. C., Zai, C. C. H., Tiwari, A. K., & Kennedy, J. L. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.05.010 · Cited by 65
Interictal Psychoses in Comparison with Schizophrenia—A Prospective Study
Tadokoro, Y., Oshima, T., & Kanemoto, K. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.01230.x · Cited by 65
In vitro and in vivo demonstration of risperidone implants in mice
Rabin, C., Liang, Y., Ehrlichman, R. S., Budhian, A., Metzger, K. L., Majewski-Tiedeken, C., Winey, K. I., & Siegel, S. J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.08.003 · Cited by 64
Risk of Treatment-Emergent Diabetes Mellitus in Patients Receiving Antipsychotics
Citrome, L. L., Holt, R. I., Zachry, W. M., Clewell, J. D., Orth, P. A., Karagianis, J. L., & Hoffmann, V. P. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k141 · Cited by 64
Metadata
- Authors
- Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., Severe, J., & Hsiao, J. K.
- Affiliations
- New York State Psychiatric Institute (US)
- Duke University (US)
- Yale University (US)
- University of North Carolina at Chapel Hill (US)
- National Institutes of Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-09-22
- Volume
- 353
- Issue
- 12
- Pages
- 1209-1223
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2159155203
- Cited by
- 5,892
- References
- 32
- Citations by year
- 2026: 95 · 2025: 89 · 2024: 135 · 2023: 129 · 2022: 191 · 2021: 166 · 2020: 338 · 2019: 207 · 2018: 211 · 2017: 220 · 2016: 231 · 2015: 277 · 2014: 325 · 2013: 361 · 2012: 379
- FWCI
- 258.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Case Western Reserve University
- Foundation of Hope for Research and Treatment of Mental Illness
- Otsuka Pharmaceutical
- National Institutes of Health (n01mh90001-21-0-0)
- University of North Carolina at Chapel Hill
- National Institute of Mental Health (N01 MH90001, MH90001)
- Janssen Pharmaceuticals
- School of Medicine, University of North Carolina at Chapel Hill
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- schizophrenia, antipsychotic drugs, atypical antipsychotics, typical antipsychotics, perphenazine, olanzapine, quetiapine, risperidone, ziprasidone, treatment discontinuation, treatment efficacy, adverse effects, weight gain, metabolic effects, extrapyramidal symptoms, chronic schizophrenia, double-blind comparison, long-term treatment
- MeSH terms
- Quetiapine Fumarate, Olanzapine, Adult, Benzodiazepines, Chronic Disease, Dibenzothiazepines, Double-Blind Method, Female, Humans, Lipids, Male, Patient Compliance, Perphenazine, Piperazines, Schizophrenia, Thiazoles, Antipsychotic Agents, Weight Gain, Proportional Hazards Models, Treatment Outcome, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
